文献
J-GLOBAL ID:202002263183520573
整理番号:20A2763113
ボルテゾミブ誘発低ナトリウム血症: トルバプタン治療は再発性骨髄腫におけるレナリドマイド,ボルテゾミブおよびデキサメタゾン治療の継続を可能にする【JST・京大機械翻訳】
Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
著者 (6件):
O’Connor-Byrne N.
(Academic Department of Haematology, Coleman Byrne Unit, Beaumont Hospital/RCSI Medical School, Dublin 9, Ireland)
,
Glavey S.
(Academic Department of Haematology, Coleman Byrne Unit, Beaumont Hospital/RCSI Medical School, Dublin 9, Ireland)
,
Tudor R.
(Academic Department of Endocrinology, Beaumont Hospital/RCSI Medical School, Dublin, Ireland)
,
Murphy P.
(Academic Department of Haematology, Coleman Byrne Unit, Beaumont Hospital/RCSI Medical School, Dublin 9, Ireland)
,
Thompson C. J.
(Academic Department of Endocrinology, Beaumont Hospital/RCSI Medical School, Dublin, Ireland)
,
Quinn J.
(Academic Department of Haematology, Coleman Byrne Unit, Beaumont Hospital/RCSI Medical School, Dublin 9, Ireland)
資料名:
Experimental Hematology & Oncology (Web)
(Experimental Hematology & Oncology (Web))
巻:
8
号:
1
ページ:
1-4
発行年:
2019年
JST資料番号:
U7482A
ISSN:
2162-3619
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
イギリス (GBR)
言語:
英語 (EN)